|
1
|
Barata PC and Rini BI: Treatment of renal
cell carcinoma: Current status and future directions. CA Cancer J
Clin. 67:507–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus axitinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dabestani S, Marconi L, Hofmann F, Stewart
F, Lam TB, Canfield SE, Staehler M, Powles T, Ljungberg B and Bex
A: Local treatments for metastases of renal cell carcinoma: A
systematic review. Lancet Oncol. 15:e549–e561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ricketts CJ and Linehan WM: Multi-regional
sequencing elucidates the evolution of clear cell renal cell
carcinoma. Cell. 173:540–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang X, Zang H, Luo Y, Wu J, Fang Z, Zhu W
and Li Y: High expression of USP22 predicts poor prognosis and
advanced clinicopathological features in solid tumors: A
meta-analysis. Onco Targets Ther. 11:3035–3046. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ao N, Wang L and Liu Y: Prognostic and
clinicopathological significance of ubiquitin-specific protease 22
overexpression in cancers: Evidence from a meta-analysis. Onco
Targets Ther. 10:5533–5540. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong
S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, et al: USP22
deficiency leads to myeloid leukemia upon oncogenic Kras activation
through a PU.1-dependent mechanism. Blood. 132:423–434. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim PJ, Plescia J, Clevers H, Fearon ER
and Altieri DC: Survivin and molecular pathogenesis of colorectal
cancer. Lancet. 362:205–209. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arber C, Feng X, Abhyankar H, Romero E, Wu
MF, Heslop HE, Barth P, Dotti G and Savoldo B: Survivin-specific T
cell receptor targets tumor but not T cells. J Clin Invest.
125:157–168. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Campbell CS and Desai A: Tension sensing
by Aurora B kinase is independent of survivin-based centromere
localization. Nature. 497:118–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saenz DT, Fiskus W, Manshouri T, Mill CP,
Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, et al:
Targeting nuclear β-catenin as therapy for post-myeloproliferative
neoplasm secondary AML. Leukemia. 33:1373–1386. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krambeck AE, Dong H, Thompson RH, Kuntz
SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker
AS and Kwon ED: Survivin and b7-h1 are collaborative predictors of
survival and represent potential therapeutic targets for patients
with renal cell carcinoma. Clin Cancer Res. 13:1749–1756. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiong C, Liu H, Chen Z, Yu Y and Liang C:
Prognostic role of survivin in renal cell carcinoma: A system
review and meta-analysis. Eur J Intern Med. 33:102–107. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altieri DC: Survivin and apoptosis
control. Adv Cancer Res. 88:31–52. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vong QP, Cao K, Li HY, Iglesias PA and
Zheng Y: Chromosome alignment and segregation regulated by
ubiquitination of survivin. Science. 310:1499–1504. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldstein NS: The current state of renal
cell carcinoma grading. Union internationale contre le cancer
(UICC) and the American joint committee on cancer (AJCC). Cancer.
80:977–980. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng F, Luo F, Lv S, Zhang H, Cao C, Chen
X, Wang S, Li Z, Wang X, Dou X, et al: A monoclonal antibody
targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer
cells to fibronectin by suppressing the FAK/p130cas signaling
pathway. Anticancer Drugs. 25:663–672. 2014.PubMed/NCBI
|
|
19
|
Cikos S, Bukovska A and Koppel J: Relative
quantification of mRNA: Comparison of methods currently used for
real-time PCR data analysis. BMC Mol Biol. 8:1132007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang B, Liang X, Tang F, Zhang J, Zeng S,
Jin S, Zhou L, Kudo Y and Qi G: Expression of USP22 and survivin is
an indicator of malignant behavior in hepatocellular carcinoma. Int
J Oncol. 47:2208–2216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Melo-Cardenas J, Zhang Y, Zhang DD and
Fang D: Ubiquitin-specific peptidase 22 functions and its
involvement in disease. Oncotarget. 7:44848–44856. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ning J, Zhang J, Liu W, Lang Y, Xue Y and
Xu S: Overexpression of ubiquitin-specific protease 22 predicts
poor survival in patients with early-stage non-small cell lung
cancer. Eur J Histochem. 56:e462012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu T, Liu J, Chen Q, Jin S, Mi S, Shao W,
Kudo Y, Zeng S and Qi G: Expression of USP22 and the chromosomal
passenger complex is an indicator of malignant progression in oral
squamous cell carcinoma. Oncol Lett. 17:2040–2046. 2019.PubMed/NCBI
|
|
24
|
Melucci E, Cosimelli M, Carpanese L, Pizzi
G, Izzo F, Fiore F, Golfieri R, Giampalma E, Sperduti I, Ercolani
C, et al: Decrease of survivin, p53 and Bcl-2 expression in
chemorefractory colorectal liver metastases may be predictive of
radiosensivity radiosensivity after radioembolization with
yttrium-90 resin microspheres. J Exp Clin Cancer Res. 32:132013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li G, Xie B, Li X, Chen Y, Wang Q, Xu Y,
Xu-Welliver M and Zou L: Down-regulation of survivin and
hypoxia-inducible factor-1 α by β-elemene enhances the
radiosensitivity of lung adenocarcinoma xenograft. Cancer Biother
Radiopharm. 27:56–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
